Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Wuxi Biologics (Cayman) ( (HK:2269) ) has provided an announcement.
WuXi Biologics (Cayman) Inc. has announced it will hold conference calls on August 20, 2025, to present its 2025 interim financial results and business operations. This initiative aims to provide shareholders and potential investors with a comprehensive understanding of the company’s performance, although they are cautioned about the forward-looking nature of some statements in the presentation.
The most recent analyst rating on (HK:2269) stock is a Buy with a HK$36.00 price target. To see the full list of analyst forecasts on Wuxi Biologics (Cayman) stock, see the HK:2269 Stock Forecast page.
More about Wuxi Biologics (Cayman)
WuXi Biologics (Cayman) Inc. is a company incorporated in the Cayman Islands, operating in the biopharmaceutical industry. It focuses on providing end-to-end solutions for biologics discovery, development, and manufacturing, catering to the global market.
Average Trading Volume: 50,506,397
Technical Sentiment Signal: Buy
Current Market Cap: HK$125.9B
See more data about 2269 stock on TipRanks’ Stock Analysis page.